Phase IV data strengthen case for Toviaz in competitive overactive bladder market
22:05 EDT 6 Aug 2012 | SCRIP
Pfizer has unveiled Phase IV results for its two overactive bladder (OAB) drugs at a time when new competitors are threatening the dominance of antimuscarinic agents, which are the current standard of care. Astellas will launch.....
Original Article: Phase IV data strengthen case for Toviaz in competitive overactive bladder market
More From BioPortfolio on "Phase IV data strengthen case for Toviaz in competitive overactive bladder market"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
